Research Analysts Issue Forecasts for Neurogene Q1 Earnings

Key Points

• William Blair has issued a negative outlook for Neurogene, revising its Q1 2026 earnings per share forecast to ($1.38), down from ($1.36).
• The company's current full-year earnings estimate stands at ($4.27) per share, with projections for subsequent quarters also reflecting increasing losses.
• Despite recent earnings beating analyst expectations, the stock has experienced a significant decline of 44% in value, leading to diverse assessments from multiple analysts.

Neurogene Inc. (NASDAQ:NGNE - Free Report) - Equities research analysts at William Blair reduced their Q1 2026 earnings per share estimates for Neurogene in a report issued on Tuesday, August 12th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($1.38) for the quarter, down from their previous estimate of ($1.36). The consensus estimate for Neurogene's current full-year earnings is ($4.27) per share. William Blair also issued estimates for Neurogene's Q2 2026 earnings at ($1.30) EPS, Q3 2026 earnings at ($1.33) EPS, Q4 2026 earnings at ($1.36) EPS and FY2026 earnings at ($5.37) EPS.

Other analysts have also issued reports about the stock. Craig Hallum started coverage on shares of Neurogene in a research note on Tuesday, June 17th. They issued a "buy" rating and a $50.00 price objective for the company. Baird R W lowered shares of Neurogene from a "strong-buy" rating to a "hold" rating in a report on Friday, May 16th. Robert W. Baird downgraded shares of Neurogene from an "outperform" rating to a "neutral" rating and dropped their price objective for the company from $38.00 to $24.00 in a research note on Friday, May 16th. HC Wainwright cut their price objective on shares of Neurogene from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Finally, BMO Capital Markets restated an "outperform" rating and set a $26.00 target price (up previously from $22.00) on shares of Neurogene in a report on Thursday, June 12th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Neurogene has a consensus rating of "Moderate Buy" and a consensus target price of $46.17.

Neurogene Price Performance

Shares of NASDAQ:NGNE traded down $0.6450 during trading on Thursday, reaching $19.8050. 42,283 shares of the company were exchanged, compared to its average volume of 229,197. Neurogene has a 12-month low of $6.88 and a 12-month high of $74.49. The business's fifty day simple moving average is $20.35 and its 200-day simple moving average is $17.33. The firm has a market capitalization of $282.62 million, a PE ratio of -4.61 and a beta of 1.69.

Neurogene (NASDAQ:NGNE - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($1.05) earnings per share for the quarter, beating analysts' consensus estimates of ($1.15) by $0.10.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE boosted its holdings in Neurogene by 81.6% in the second quarter. Bank of America Corp DE now owns 95,401 shares of the company's stock worth $1,426,000 after acquiring an additional 42,880 shares in the last quarter. Schroder Investment Management Group purchased a new position in shares of Neurogene in the 2nd quarter valued at approximately $451,000. PNC Financial Services Group Inc. boosted its stake in Neurogene by 43.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company's stock worth $61,000 after purchasing an additional 1,232 shares in the last quarter. Jennison Associates LLC boosted its stake in Neurogene by 55.0% in the 2nd quarter. Jennison Associates LLC now owns 167,563 shares of the company's stock worth $2,505,000 after purchasing an additional 59,479 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Neurogene by 17.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company's stock worth $82,000 after purchasing an additional 1,059 shares during the last quarter. 52.37% of the stock is owned by institutional investors and hedge funds.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.